AbbVie (ABBV) and Bristol-Myers Squibb (BMY) will collaborate in a Phase 1/2 clinical trial assessing the former's antibody-drug conjugate Rova-T (rovalpituzumab tesirine) and the latter's Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) in patients with relapsed extensive-stage small cell lung cancer (SCLC). The objective is to determine if the targeted cell killing and antigen release caused by Rova-T enhances the effect of immunotherapy. Patient recruiting should start later this year.